High-risk, HR+, HER2-, early-stage BC patients continue to benefit from abemaciclib

(American Association for Cancer Research) Extended follow-up data from the phase III monarchE trial showed that adding the cyclin-dependent kinase (CDK) inhibitor abemaciclib (Verzenio) to standard adjuvant endocrine therapy continued to improve invasive disease-free survival (IDFS) among patients with high-risk, node-positive, early-stage, HR-positive, HER2-negative breast cancer, according to data presented at the 2020 San Antonio Breast Cancer Symposium.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news